TULIO EDUARDO FLESCH PFIFFER
Índice h a partir de 2011
9
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
12 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 12
bookPart Câncer de Esôfago(2014) HOFF, Paulo M. G.; SABBAGA, Jorge; COSTA, Frederico P.; FERNANDES, Gustavo dos Santos; CAPARELI, Fernanda; SARAGIOTTO, Daniel; PEREIRA, Guilherme Stelko; PFIFFER, Tulio; BEZERRA NETO, João EvangelistabookPart Câncer de Canal Anal(2014) HOFF, Paulo M. G.; SABBAGA, Jorge; COSTA, Frederico P.; FERNANDES, Gustavo dos Santos; CAPARELI, Fernanda; SARAGIOTTO, Daniel; PEREIRA, Guilherme Stelko; PFIFFER, Tulio; BEZERRA NETO, João Evangelista- Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma(2015) FONSECA, Leonardo Gomes Da; BARROSO-SOUSA, Romualdo; BENTO, Afonso Da Silva Alves; BLANCO, Bruna Paccola; VALENTE, Gabriel Luis; PFIFFER, Tulio Eduardo Flesch; HOFF, Paulo Marcelo; SABBAGA, JorgeSorafenib demonstrated a survival benefit in the treatment of advanced hepatocellular carcinoma (HCC) in phase III trials. However, almost all the patients included in those trials exhibited well-preserved liver function (Child-Pugh A). The aim of this study was to describe our experience with sorafenib in Child-Pugh B HCC patients. A database of patients with advanced HCC treated with sorafenib was retrospectively evaluated. The median overall survival of Child-Pugh B patients (n=20) was 2.53 months [95% confidence interval (CI): 0.33-5.92 months] and of Child-Pugh A patients (n=100) 9.71 months (95% CI: 6.22-13.04). Child-Pugh B patients had a significantly poorer survival compared to Child-Pugh A patients (P=0.002). The toxicities were similar between the two groups. Metastasis, vascular invasion and alpha-fetoprotein level >1,030 ng/ml were not associated with survival among Child-Pugh B patients (P=0.281, 0.189 and 0.996, respectively). Although the survival outcomes were worse in Child-Pugh B patients treated with sorafenib, the toxicity profile was manageable. Therefore, there remains the question of whether to treat this subgroup of patients and more data are required to define the role of sorafenib in the context of liver dysfunction.
bookPart Câncer de Pâncreas e Vias Biliares(2014) HOFF, Paulo M. G.; SABBAGA, Jorge; COSTA, Frederico P.; FERNANDES, Gustavo dos Santos; CAPARELI, Fernanda; SARAGIOTTO, Daniel; PEREIRA, Guilherme Stelko; PFIFFER, Tulio; BEZERRA NETO, João EvangelistabookPart Câncer do Intestino Delgado(2014) HOFF, Paulo M. G.; SABBAGA, Jorge; COSTA, Frederico P.; FERNANDES, Gustavo dos Santos; CAPARELI, Fernanda; SARAGIOTTO, Daniel; PEREIRA, Guilherme Stelko; PFIFFER, Tulio; BEZERRA NETO, João EvangelistabookPart Câncer Colorretal(2014) HOFF, Paulo M. G.; SABBAGA, Jorge; COSTA, Frederico P.; FERNANDES, Gustavo dos Santos; CAPARELI, Fernanda; SARAGIOTTO, Daniel; PEREIRA, Guilherme Stelko; PFIFFER, Tulio; BEZERRA NETO, João EvangelistaconferenceObject Pretreatment neutrophil to lymphocyte ratio and prognosis of patients with advanced hepatocelullar carcinoma treated with sorafenib.(2014) FONSECA, Leonardo Gomes; BARROSO-SOUSA, Romualdo; BLANCO, Bruna Paccola; VALENTE, Gabriel Luls; BRAGHLROLL, Maria Ignez Freltas Melro; PFIFFER, Tullo Eduardo Flesch; SABBAGA, Jorge; HOFF, Paulo MarcelobookPart Tumor Estromal do Trato Gastrintestinal (GIST)(2014) HOFF, Paulo M. G.; SABBAGA, Jorge; COSTA, Frederico P.; FERNANDES, Gustavo dos Santos; CAPARELI, Fernanda; SARAGIOTTO, Daniel; PEREIRA, Guilherme Stelko; PFIFFER, Tulio; BEZERRA NETO, João EvangelistabookPart Câncer de Estômago(2014) HOFF, Paulo M. G.; SABBAGA, Jorge; COSTA, Frederico P.; FERNANDES, Gustavo dos Santos; CAPARELI, Fernanda; SARAGIOTTO, Daniel; PEREIRA, Guilherme Stelko; PFIFFER, Tulio; BEZERRA NETO, João EvangelistabookPart Carcinoma Hepatocelular(2014) HOFF, Paulo M. G.; SABBAGA, Jorge; COSTA, Frederico P.; FERNANDES, Gustavo dos Santos; CAPARELI, Fernanda; SARAGIOTTO, Daniel; PEREIRA, Guilherme Stelko; PFIFFER, Tulio; BEZERRA NETO, João Evangelista